When you’re choosing an electronic data capture (EDC) platform, comparing top vendors is essential. This is an honest, feature-by-feature comparison of Castor EDC and Medidata Rave EDC to help you understand where each excels and which fits your study, organization, and regulatory context.
Decentralised clinical trials span a spectrum: from fully remote (no site visits) to hybrid (some site, some remote). The right platform depends on where your study sits on that spectrum and whether you need home health logistics coordination. If running a truly decentralised programme with home visits and advanced patient coordination needs, Medable’s ecosystem may add value. If you need a straightforward, transparent alternative for unified EDC plus eCOA plus eConsent for hybrid or traditional designs, Castor is often simpler and more cost-effective.
A high-level look at where the two platforms differ most.
| Feature | Castor EDC | Medidata Rave EDC |
|---|---|---|
| Best for | Academic, emerging biopharma, medical devices, fast implementation | Large pharma, CROs, global Phase III, enterprise ecosystems |
| Deployment | Cloud-native SaaS | Cloud SaaS |
| Study builder | No-code eCRF designer | Code-based with templates |
| eCOA/ePRO | Native, integrated | Medidata Patient Cloud (add-on) |
| eConsent | Native, built-in | Native (Medidata Consent, integrates with Rave EDC) |
| RTSM | Yes, native randomization (trial supply via partner) | Rave RTSM (integrated) |
| RWE/Registry | CastorRWE integrated | Separate platforms |
| Regulatory compliance | 21 CFR Pt 11, ICH GCP, GDPR, EU MDR, ISO 27001 | supports 21 CFR Part 11 compliance, ICH GCP, global regulatory submission history, GDPR, ISO 27001/27701, SOC 2 Type II |
| Implementation time | 3-4 wks low-complexity / standard, 4-8 managed (8-12 high), vs a 10-14 wk legacy average | Weeks to months (consultant-led) |
| Pricing model | Predictable flat-rate study licensing, no per-subject fees | Pricing not publicly disclosed |
| Support model | Built-in support team | Tiered support + consultant network |
A high-level look at where the two platforms differ most.
| Feature | Castor EDC | Medidata Rave EDC | Advantage |
|---|---|---|---|
| Cloud-native architecture | Yes | Yes | Comparable |
| No-code eCRF builder | Yes | No | ✓ Castor |
| Integrated eCOA/ePRO | Yes | Patient Cloud (separate) | ✓ Castor |
| Integrated eConsent | Yes | Yes (Medidata Consent) | Comparable |
| RTSM | Native randomization (variable block, stratification, blinding controls). Trial supply / kit logistics via partner integration. | Yes | Comparable |
| EU MDR/PMCF support | Purpose-built | Supported | ✓ Castor |
| Decentralized trial (DCT) support | Yes | Yes | Comparable |
| Regulatory submission history | 160+ countries (cumulative, to date) | FDA, EMA, PMDA, extensive | Medidata |
| Implementation speed | 3-4 wks low-complexity / standard, 4-8 managed (8-12 high), vs a 10-14 wk legacy average | Weeks to months | ✓ Castor |
| Pricing transparency | Predictable flat-rate study licensing, no per-subject fees | Pricing not publicly disclosed | Comparable |
| Medical device focus | Strong (EU MDR/PMCF) | Standard support | ✓ Castor |
| Academic/IIT suitability | Excellent fit | Enterprise-focused | ✓ Castor |
| AI/analytics capability | Core analytics | Medidata AI (advanced) | Medidata |
| Global regulatory coverage | 160+ countries (cumulative, to date), strong EU | PMDA, global enterprise focus | Medidata |
An honest overview of what each platform does well, and where it has trade-offs.
Castor EDC is a cloud-native, SaaS-based electronic data capture platform founded in Amsterdam and trusted by academic institutions, emerging biopharma companies, medical device manufacturers, and contract research organizations worldwide. The platform is designed for simplicity, speed, and transparency.
Castor’s defining strengths include a no-code eCRF builder (meaning study teams can design case report forms without programmers or implementation consultants), a unified platform integrating EDC, eCOA, eConsent, native randomization, and real-world evidence capabilities. The platform is particularly strong for medical device companies pursuing EU MDR post-market clinical follow-up (PMCF) studies, and for academic investigators running investigator-initiated trials (IITs) who need speed without enterprise budgets.
Castor is Enables FDA 21 CFR Part 11 and EU Annex 11 compliance, GDPR-compliant, and supports ICH GCP standards. The platform is ISO 27001 certified and audited for security. Studies are live in 3-4 wks low-complexity / standard, 4-8 managed (8-12 high), vs a 10-14 wk legacy average. Pricing is transparent and per-study, with no long-term enterprise contracts.
Medidata Rave EDC, owned by Dassault Systèmes (acquired in 2019), is the market-leading enterprise EDC platform trusted by large pharmaceutical companies, global CROs, and enterprise-scale research organizations. Rave is embedded in the standard operating procedures (SOPs) of many large pharma companies and is the de facto EDC in large Phase III global studies.
Rave’s core strengths are scale, regulatory submission history, and integration depth. The platform has been used in thousands of submissions to the FDA, EMA, PMDA, and global health authorities, making it the gold standard for large-scale, highly regulated clinical trials. Rave integrates deeply with pharma enterprise systems (LIMS, ERP, BI tools) and supports multi-language, multi-currency global studies. Medidata also offers advanced analytics through Medidata AI, which uses machine learning to identify data quality issues and predict enrollment patterns.
Use these criteria to self-select based on your study type, organization, and requirements.
Run a time-boxed evaluation of both platforms using a representative eCRF from one of your studies. Create the same form in both tools and time the process. Request a demo that includes your specific regulatory context (such as EU MDR, a pediatric study, or a decentralized trial) and pricing based on your expected study portfolio. Talk to existing users in your therapeutic area or study type. The right platform is the one that fits your team’s skills, budget, and timeline, not the one with the most features.
Common questions from teams evaluating Castor and Medidata Rave.
Yes, but the fit depends on your study type and organization. Castor excels for academic research, emerging biopharma, medical device studies, and organizations wanting transparent, fast implementation with minimal consultant involvement. Medidata is better for large pharma and CROs with established enterprise workflows and deep regulatory submission history requirements.
Castor offers transparent, per-study SaaS pricing so you know costs upfront and can scale as you grow. Medidata uses enterprise contracts with custom pricing, typically requiring negotiation and multi-year commitments. For a single study or small portfolio, Castor is usually more cost-effective. For large enterprise portfolios, Medidata’s per-study cost may be lower at scale.
Castor enables FDA 21 CFR Part 11 and EU Annex 11 compliance, supports ICH GCP and GDPR, and is particularly strong for EU regulatory submissions (including EU MDR for medical devices). Medidata has a deeper historical submission track record globally, especially for PMDA (Asia-Pacific) and large multi-jurisdiction studies. Both are audit-ready, but Medidata’s submission portfolio is more extensive.
Castor studies typically go live in days to weeks using the no-code eCRF builder. Medidata typically requires weeks to months, with implementation often consultant-led. The difference matters most if you need fast time-to-first-patient enrollment.
Yes. Data migration is possible and Castor’s professional services team can assist. However, you’ll need to redesign eCRFs in Castor’s no-code builder (not a direct port). For ongoing studies, migration timing and study disruption are important considerations. Castor recommends discussing migration strategy during evaluation.
